Yoshimasa Shiraishi

Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer

Ying Cheng, David R. Spigel, Byoung Chul Cho et al. · New England Journal of Medicine · 2024 · 275 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Safety and efficacy of PD-1 inhibitors in non–small cell lung cancer patients positive for antinuclear antibodies

Yasuto Yoneshima, Kentaro Tanaka, Yoshimasa Shiraishi et al. · Lung Cancer · 2019 · 82 citations

Life Sciences, Oncology, Pharmacology +14

Real‐world data on NGS using the Oncomine DxTT for detecting genetic alterations in non‐small‐cell lung cancer: WJOG13019L

Shinya Sakata, Kohei Otsubo, Hisako Yoshida et al. · Cancer Science · 2021 · 71 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression

Heyan Li, Koichi Takayama, Shuo Wang et al. · Cancer Chemotherapy and Pharmacology · 2014 · 70 citations · Full text

Medicine, Oncology, Pharmacology +16

Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non–Small Cell Lung Cancer

Motoko Tachihara, Kayoko Tsujino, Takeaki Ishihara et al. · JAMA Oncology · 2023 · 65 citations · Full text

Medicine, Oncology, Radiation Oncology +16